Technology Possessed

NKGEN Co., Ltd. aims to overcome intractable blood and solid tumor cancer through chemotherapy and contribute to the well-being of patients.

• Natural killer cells currently in the development and commercialization process are high purity, and are the fourth-generation chemotherapy drugs that can be differentially produced for each target adaptation through high-tech specifications and differential culture processes.
• The NKG Enterprise Research Institute is working with CRO teams to produce standard data for domestic and overseas clinical trial approval for technology commercialization by performing technology maturity development steps through non-clinical and preclinical detailed research of core technology.

• 01

  Superior homogeneous and self-derived

  (allogeneic & autologous) cell culture technology

• 02

  IL – 2 as a cell culture essential

  Alternative Material Element Technology (Patent Application Stage)

• 03

  Source Technology and Automation of Cell Culture Solution

  Technology retention (patent application pending